Doctors said that only twice a year will patients be able to get cholesterol-lowering jobs as an alternative to statins, it was announced today.
The “game-changing” drug, Enclacerin, will be rolled out to the NHS after receiving approval from the UK Medical Watchdog.
It has been shown to be as effective as high-dose statins after getting rid of about 50% “bad” LDL cholesterol, which clings to blood vessels and increases the risk of heart attack and stroke.
Inclisiran will be given by injection once every six months, saving millions of people from the hassle of taking daily pills.
Statins have become one of the most commonly prescribed drugs in the UK, with around 88 million adults in the country relying on them.
Health Secretary Sajid Javed called the “life-saving” alternative a major step in tackling heart disease.
The revolutionary job was initially approved by the National Institute for Health and Care Excellence (NICE) for people with high cholesterol, who already have heart disease, or who have had a heart attack or stroke. That’s about 300,000 people.
Experts believe that in the next decade, medicine can save about 30,000 lives and 55,000 heart attacks and strokes.
Treatment is more effective if taken with statins, but can be used successfully by those who cannot afford pills.
This will be a lifeline for those who stop taking the pills as they get rid of the discomfort of taking the pill daily due to side effects including headaches and muscle aches.
Two out of five adults in the UK have high cholesterol, a major cause of heart disease – responsible for one in four deaths in England.
Further research is considering whether enclosure can be used as a preventative measure to help millions of British citizens fighting heart problems.
It helps the liver remove cholesterol from the blood by stopping the production of a protein called PCS-9, which reduces the organ’s ability to get rid of cholesterol.
The “World Leading” deal.
Job has been called the first easy and effective alternative to status.
It usually costs around dose 2,000 per dose – which will be £ 4,000 per patient per year – but NHS England has revealed that it has entered into a secret agreement with manufacturer Novartis.
The “world-renowned” agreement means that 300,000 people will be able to receive enclave in the next three years.
In comparison, statins cost about 20 20 per patient per year.
NHS boss Amanda Pritchard said the agreement would enable millions of people to benefit from this revolutionary treatment while also doing justice to taxpayers.
Meindert Boysen, NICE’s Deputy Chief Executive, added: “Inclisiran represents a potential game changer in preventing thousands of people from dying prematurely from heart attacks and strokes.”
Professor Kosk Ray of Imperial College London, who led the research on the drug, said: “This is great news for patients.
It was tested on patients in the UK last year and aims to play a key role in fulfilling the NHS Long Term Plan’s commitment to preventing 150,000 cardiac deaths in ten years.
Preliminary research shows that inclisiran can halve bad cholesterol in just two weeks.
Novartis CEO Vas Narasimhan had previously said the drug would “open a new chapter in the treatment of heart disease.”